Atrial fibrillation primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 14: | Line 14: | ||
**[[Beta blocker]] (a standard [[beta blocker]] is suggested) | **[[Beta blocker]] (a standard [[beta blocker]] is suggested) | ||
**[[Calcium-channel blockers]] such as [[diltiazem]] or [[verapamil]] | **[[Calcium-channel blockers]] such as [[diltiazem]] or [[verapamil]] | ||
*In [[patients]] who have been undergone [[heart|cardiac]] [[surgery]] and were on a [[beta blocker]] before the [[surgery]], continue the [[treatment]] in the absence of any [[complications]] (such as [[surgery|postoperative]] [[bradycardia]] or [[hypotension]]). | |||
*Avoid offering [[digoxin]] in [[patients]] who have been undergone [[heart|cardiac]] [[surgery]] in order to prevent [[atrial fibrillation]].<ref name="pmid34020968">{{cite journal| author=Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee| title=Atrial fibrillation: diagnosis and management-summary of NICE guidance. | journal=BMJ | year= 2021 | volume= 373 | issue= | pages= n1150 | pmid=34020968 | doi=10.1136/bmj.n1150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34020968 }} </ref> | *Avoid offering [[digoxin]] in [[patients]] who have been undergone [[heart|cardiac]] [[surgery]] in order to prevent [[atrial fibrillation]].<ref name="pmid34020968">{{cite journal| author=Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee| title=Atrial fibrillation: diagnosis and management-summary of NICE guidance. | journal=BMJ | year= 2021 | volume= 373 | issue= | pages= n1150 | pmid=34020968 | doi=10.1136/bmj.n1150 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34020968 }} </ref> | ||
Revision as of 22:11, 16 August 2021
 |
Resident Survival Guide |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation primary prevention On the Web | |
|
Directions to Hospitals Treating Atrial fibrillation primary prevention | |
|
Risk calculators and risk factors for Atrial fibrillation primary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]
Overview
Atrial Fibrillation Primary Prevention
Preventing Postoperative Atrial Fibrillation
- Offer on of the following in order to prevent atrial fibrillation development in patients who have been undergone cardiac surgery:[1]
- Amiodarone
- Beta blocker (a standard beta blocker is suggested)
- Calcium-channel blockers such as diltiazem or verapamil
- In patients who have been undergone cardiac surgery and were on a beta blocker before the surgery, continue the treatment in the absence of any complications (such as postoperative bradycardia or hypotension).
- Avoid offering digoxin in patients who have been undergone cardiac surgery in order to prevent atrial fibrillation.[1]
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (DO NOT EDIT)[2]
Rhythm Control
Pharmacological Agents for Preventing AF and Maintaining Sinus Rhythm
Upstream Therapy
| Class III: No Benefit |
| "1. Therapy with an ACE inhibitor, ARB, or statin is not beneficial for primary prevention of AF in patients without cardiovascular disease. (Level of Evidence: B)" |
| Class IIa |
| "1. An ACE inhibitor or angiotensin-receptor blocker (ARB) is reasonable for primary prevention of new-onset AF in patients with HF with reduced LVEF. (Level of Evidence: B)" |
| Class IIb |
| "1. Therapy with an ACE inhibitor or ARB may be considered for primary prevention of new-onset AF in the setting of hypertension. (Level of Evidence: B)" |
| "2. Statin therapy may be reasonable for primary prevention of new-onset AF after coronary artery surgery. (Level of Evidence: A)" |
Sources
References
- ↑ 1.0 1.1 Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee (2021). "Atrial fibrillation: diagnosis and management-summary of NICE guidance". BMJ. 373: n1150. doi:10.1136/bmj.n1150. PMID 34020968 Check
|pmid=value (help). - ↑ 2.0 2.1 January, C. T.; Wann, L. S.; Alpert, J. S.; Calkins, H.; Cleveland, J. C.; Cigarroa, J. E.; Conti, J. B.; Ellinor, P. T.; Ezekowitz, M. D.; Field, M. E.; Murray, K. T.; Sacco, R. L.; Stevenson, W. G.; Tchou, P. J.; Tracy, C. M.; Yancy, C. W. (2014). "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society". Circulation. doi:10.1161/CIR.0000000000000041. ISSN 0009-7322.